TScan Therapeutics, Inc. (TCRX) Institutional Ownership

Ownership Summary

A total of 59 institutions have reported a stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) as of December 2025, according to recent 13F filings with the SEC.

• TScan Therapeutics saw its institutional ownership percentage fell to 24.0% in December 2025 from 27.1% in September 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 1.54%, with a year-over-year a decrease of 35.16% in the count of filers.
• The latest 13F cycle for TScan Therapeutics reveals that of 59 total investors, 27 funds grew their exposure, whereas 19 reduced theirs and 13 made no changes.
• The aggregate institutional position in TScan Therapeutics now stands at 30.67Mn shares as of December 2025, after investors increased their holdings (up by 465.35K shares quarter on quarter which is down 10.87Mn shares year over year).
• Lynx1 Capital Management LP continues to be the largest institutional holder of TScan Therapeutics as of December 31, 2025, with a position of 8.02Mn shares, representing 6.29% of the company's outstanding stock.
• Among the most significant buyers of TScan Therapeutics during December 2025 were Aberdeen Group plc (430.42K), RENAISSANCE TECHNOLOGIES LLC (311.15K), JANE STREET GROUP, LLC (306.97K), MARSHALL WACE, LLP (292.61K), TWO SIGMA INVESTMENTS, LP (231.78K).
• Leading sellers of TScan Therapeutics stock in December 2025 included MORGAN STANLEY (621.71K), TANG CAPITAL MANAGEMENT LLC (553.87K), BlackRock, Inc. (534.07K), CITADEL ADVISORS LLC (227.87K), JPMORGAN CHASE & CO (204.40K).
• The top 10 institutional holders of TScan Therapeutics for the quarter ending December 2025 included Lynx1 Capital Management LP (8.02Mn), BVF INC/IL (5.23Mn), BAKER BROS. ADVISORS LP (2.78Mn), VANGUARD GROUP INC (2.48Mn), BlackRock, Inc. (1.85Mn), Aberdeen Group plc (1.79Mn), Deer Management Co. LLC (1.25Mn), RENAISSANCE TECHNOLOGIES LLC (1.14Mn), TWO SIGMA INVESTMENTS, LP (651.18K), DC Funds, LP (630.00K).